Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough

Stock Track

04-17

Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.

BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.

Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1181488210"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181488210\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1181488210?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181488210","market":"us","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.</p>\n\n<p>BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.</p>\n\n<p>Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-04-17 21:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.</p>\n\n<p>BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.</p>\n\n<p>Adding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"諾和諾德","start_time":0,"source_url":"","article_id":"1181488210","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181488210","pubTimestamp":1744895823,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S  shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.BMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"由于分析师下调评级和竞争对手的突破，诺和诺德股价盘前暴跌7.57%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares retreated 7.57% in pre-market trading on Thursday, following a significant downgrade from BMO Capital and news of a breakthrough from competitor Eli Lilly in the weight loss medication market.\nBMO Capital downgraded Novo Nordisk from Outperform to Market Perform, slashing its price target from $105 to $64. This dramatic reduction in outlook has sparked concerns among investors about the company's future growth prospects in the highly competitive obesity and diabetes treatment sectors.\nAdding to the pressure, Eli Lilly announced that its experimental pill, orforglipron, achieved an average weight loss of 7.9% and improved blood sugar levels in overweight patients with type 2 diabetes during a late-stage trial. This development poses a significant threat to Novo Nordisk's market position, as Lilly's oral medication could potentially compete with Novo's injectable treatments like Ozempic and Wegovy. The news sent Eli Lilly's shares soaring nearly 13% in pre-market trading, further highlighting the shift in investor sentiment within the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}